Literature DB >> 10680650

Prevention of edema disease in pigs by passive immunization.

M Johansen1, L O Andresen, L K Thomsen, M E Busch, H Wachmann, S E Jorsal, C L Gyles.   

Abstract

The effect of treatment with verotoxin 2e (VT2e) specific antiserum was evaluated in 3 Danish pig herds with edema disease (ED). The antiserum was prepared by immunizing horses with a VT2e toxoid. The study was performed as a randomized blind field trial with parallel treatment and control groups. There were approximately 50 piglets in each group in each of the 3 herds and 741 piglets were included in the study (244 from herd A, 249 from herd B, and 247 from herd C). Treatment groups received 2, 4, or 6 mL anti-VT2e serum intramuscularly the day before weaning. Control groups were treated with 6 mL normal horse serum or 6 mL RPMI 1640 medium as placebo. All pigs that died in the trial period (1 d before weaning to 44 d after weaning) were examined pathologically and microbiologically. Mortality due to ED, mortality due to other causes, and adverse effects due to treatment were recorded. As there was no mortality due to ED, herd B was excluded from statistical calculations on mortality. The content of horse antibodies specific to VT2e in serum from pigs was analyzed in an indirect ELISA. A higher dose of anti-VT2e serum was reflected in higher optical density values in the indirect ELISA. Transient adverse reactions, seen as vomiting, ataxia, and cyanosis, occurred shortly after the injection of horse serum in 1.5% of the pigs, and one pig died. There were no statistically significant differences in mortality due to other causes among the 3 treatment groups in herds A and C. Only pigs from which F18+, VT2e+, ST-, LT- hemolytic E. coli (0139 or O-rough) was isolated were diagnosed as dead due to ED. Deaths due to ED in the control groups were 8.1% and 12.0% in herds A and C, respectively, compared with 0% and 0.7% in the corresponding serum groups. The difference between treatment and control groups was statistically significant (P<0.0001). It was not possible to establish an effect of dose (2, 4, or 6 mL) of anti-VT2e serum, because only one pig died of ED in the treatment groups. It was concluded that passive immunization by intramuscular injection of a VT2e-specific antiserum can be used for protecting piglets against ED.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10680650      PMCID: PMC1189574     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  9 in total

1.  Prevention of edema disease in pigs by vaccination with verotoxin 2e toxoid.

Authors:  M Johansen; L O Andresen; S E Jorsal; L K Thomsen; T E Waddell; C L Gyles
Journal:  Can J Vet Res       Date:  1997-10       Impact factor: 1.310

2.  Immunization of pigs with a purified Shiga-like toxin II variant toxoid.

Authors:  D L MacLeod; C L Gyles
Journal:  Vet Microbiol       Date:  1991-11       Impact factor: 3.293

3.  Oedema disease caused by O-rough Escherichia coli.

Authors:  F M Aarestrup; S E Jorsal; P Ahrens; C Wiuff; F Scheutz
Journal:  Vet Rec       Date:  1996-10-12       Impact factor: 2.695

Review 4.  The pathogenesis of edema disease in pigs. A review.

Authors:  H Imberechts; H De Greve; P Lintermans
Journal:  Vet Microbiol       Date:  1992-06-01       Impact factor: 3.293

5.  Prevalence of F107 fimbriae on Escherichia coli isolated from pigs with oedema disease or postweaning diarrhoea.

Authors:  H Imberechts; H U Bertschinger; M Stamm; T Sydler; P Pohl; H De Greve; J P Hernalsteens; M Van Montagu; P Lintermans
Journal:  Vet Microbiol       Date:  1994-06       Impact factor: 3.293

6.  Detection of fimbrial and toxin genes in Escherichia coli and their prevalence in piglets with diarrhoea. The application of colony hybridization assay, polymerase chain reaction and phenotypic assays.

Authors:  B Ojeniyi; P Ahrens; A Meyling
Journal:  Zentralbl Veterinarmed B       Date:  1994-03

7.  Vaccination with genetically modified Shiga-like toxin IIe prevents edema disease in swine.

Authors:  B T Bosworth; J E Samuel; H W Moon; A D O'Brien; V M Gordon; S C Whipp
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

8.  Reproduction of edema disease of swine with purified Shiga-like toxin-II variant.

Authors:  D L MacLeod; C L Gyles; B P Wilcock
Journal:  Vet Pathol       Date:  1991-01       Impact factor: 2.221

9.  Interaction of verotoxin 2e with pig intestine.

Authors:  T E Waddell; C A Lingwood; C L Gyles
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

  9 in total
  5 in total

1.  Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications.

Authors:  Abhineet S Sheoran; Susan Chapman-Bonofiglio; Barrett R Harvey; Jean Mukherjee; George Georgiou; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

2.  Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection.

Authors:  Jean Mukherjee; Kerry Chios; Dianne Fishwild; Deborah Hudson; Susan O'Donnell; Stephen M Rich; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants.

Authors:  Abhineet S Sheoran; Susan Chapman; Pradeep Singh; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

4.  Systematic review and network meta-analysis to compare vaccine effectiveness against porcine edema disease caused by Shiga toxin-producing Escherichia coli.

Authors:  Sim-In Lee; Eurade Ntakiyisumba; Gayeon Won
Journal:  Sci Rep       Date:  2022-04-19       Impact factor: 4.996

Review 5.  Passive immunisation, an old idea revisited: Basic principles and application to modern animal production systems.

Authors:  Chris J Hedegaard; Peter M H Heegaard
Journal:  Vet Immunol Immunopathol       Date:  2016-04-26       Impact factor: 2.046

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.